Paclitaxel-eluting stent Taxcor: first application in man.
The safety and efficacy of the second-generation paclitaxel-eluting stent with bioactive matrix Taxcor after implantation in de novo coronary lesions at 6 months is unknown. In this single-center non-controlled study, 45 patients with mean de novo coronary lesions of 12.1+/-1.9 mm in length and mean reference diameter of 2.9+/-0.3 mm received the paclitaxel-eluting stent (Taxcor). Fifty stents were implanted. Clinical and angiographic follow-up were performed after 6 months. It was the first time that the Taxcor stent was applied in patients. Mean stent diameter was 3.0+/-0.3 mm and mean length 21.2+/-5.9 mm. Four patients did not consent to control angiography at 6 months. Mean minimal lumen diameter increased from 1.1+/-0.1 mm (pre-stent) to 2.7+/-0.3 mm (post-stent) and had slightly decreased to 2.4+/-0.6 mm at 6-month follow-up. Mean acute lumen gain was 1.6+/-0.3 mm. Mean reference-vessel diameter was 2.9+/-0.3 mm at all time points. Mean percentage-diameter stenosis decreased from 62.6%+/-5.6 (pre-stent) to 9.1+/-6.0% (post-stent) and had increased slightly to 18.4+/-6.5% after 6 months. Mean late lumen loss was 0.3+/-0.4 mm. All patients remained symptom-free during the 6-month follow-up with no cases of acute myocardial infarction or death reported. No procedure-related complications occurred and no acute or subacute stent thromboses were reported. Control angiography showed binary restenosis (percentage-diameter stenosis >50%) in one patient, in whom coronary intervention was performed subsequently. The paclitaxel-eluting stent Taxcor appeared to be effective and safe up to 6 months following implantation.